Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Russell 2000 ETF (IWM) Price & Performance

Adaptive Biotechnologies CorpTrade
iShares Russell 2000 ETFTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs iShares Russell 2000 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.08 (market cap $4.04B), while iShares Russell 2000 ETF trades at $301.36. Which is the better fit depends on your goals.

ADPTIWM
Market Cap
$4.04B
Sector
Health
52-Week High
$25.45$301.69
52-Week Low
$12.30$225.45
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

iShares Russell 2000 ETF

IWM trades at $302.3, up 0.77% with a bullish technical outlook supported by moving averages, though RSI suggests mild overbought conditions. The ETF, tracking the Russell 2000 small-cap index, benefits from institutional favor due to deep liquidity and options markets. Small caps are outperforming large caps year-to-date, with the Russell 2000 up approximately 20% as of July 17, 2026 (24/7 Wall Street).

Outlook remains positive for small-cap exposure amid broadening market rally, but risks include higher volatility and economic sensitivity. Investors gain diversified small-cap access, yet should monitor valuation gaps versus alternatives and interest rate impacts highlighted by Goldman Sachs on July 7, 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM